The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The study met its primary endpoint and all 11 secondary efficacy endpoints
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Captured microbes are then neutralized on engineered microbicidal surfaces
76 of 180 long COVID-associated genes also linked to ME
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Subscribe To Our Newsletter & Stay Updated
